ASCO 2026 hints at future role for VEGF-targeted cancer drugs as complement to immunotherapy
read at Endpoints ↗Neutral
At the recent ASCO meeting, experts discussed the outlook for VEGF-targeted therapies in oncology.
Earlier hopes that this new class could match the blockbuster success of pembrolizumab (Keytruda) have been tempered.
Analysts now view VEGF agents as potentially filling gaps left by immunotherapy rather than supplanting it.
The article notes that definitive conclusions will require more data from ongoing trials.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “What’s next for VEGF? #ASCO26 offered clues, but answers will have to wait”
read at Endpoints ↗91 words · retrieved Jun 2
comments(0)
5-min edit window · permanent after that